Overall, the current pioneering preclinical findings reveal the potential of LY-induced S6K1 blockage as an efficacious therapeutic treatment to hamper fat mass expansion and relieve the burden of dyslipidemia and fatty liver in obese patients. This evidence concerns the gene RPS6KB1 and fatty liver disease.